MarkSebastianSulkowskiMD

Professor of Medicine, Johns Hopkins University School of Medicine; Senior Associate Dean for Clinical Trials; Director Division of Infectious Diseases, Johns Hopkins Bayview Medical Center; Medical Director, Viral Hepatitis Center

Join to view full profile

Dr. Sulkowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sulkowski's full profile

Already have an account?

Office
10751 Falls Road
Falls Concourse Ste 412
Lutherville, MD 21093
Phone+1 410-583-2900

Fax+1 410-583-2654

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 1995 - 1998
Duke University HospitalResidency, Internal Medicine, 1992 - 1995
Lewis Katz School of Medicine at Temple UniversityClass of 1992

Certifications & Licensure

MD State Medical License 1996 - 2025
NC State Medical License 1994 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2011

Clinical Trials

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
Completed
Not Applicable
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Completed
Phase 3
Management of Hepatitis C in HIV-Infected and Uninfected IDUs Start of enrollment: 2004 Jan 01
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Start of enrollment: 2007 Jul 01
Completed
Phase 1
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults Start of enrollment: 2010 Sep 01
Completed
Phase 1
Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs) Start of enrollment: 2021 Mar 31
Completed
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Completed
HBV-HIV Coinfection Research Network Start of enrollment: 2014 Apr 01
Completed
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy Start of enrollment: 2015 Sep 16
Terminated
Phase 2
deLIVER: Direct Acting Antiviral Effects on the Liver Start of enrollment: 2017 Jan 01
Completed
Phase 4
Rapid HCV Treatment Access for Persons Who Use Drugs Start of enrollment: 2021 Aug 06
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation.
Jaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, Kenneth Bowden, Prasanthy Balasubramaniam
The Journal of Infectious Diseases. 2024-12-04
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.
Pamela M Murnane, Majid Afshar, Gabriel Chamie, Robert L Cook, Tekeda Ferguson
The American Journal of Gastroenterology. 2024-10-31
1 citations
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, David R Boulware, Matthew W McCarthy
JAMA Network Open. 2024-10-01

Journal Articles

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-Infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study
Mandana Khalili, Mark Sulkowski, Marc G Ghany, Richard K Sterling, Raymond T Chung, David E Kleiner, Mamta K Jain, Nature

Lectures

Hepatitis C Management: State of the Art 2013
Hepatitis C Management, New York, New York - 5/9/2013
Hepatobiliary Disease in Clinical Practice: Update XX
University of Miami, Miami, Florida - 2/22/2013

Press Mentions

Biden: ‘Every American Can Do Their Part’ to Eliminate Viral Hepatitis Epidemic in USMay 20th, 2023
HCV Elimination Represents ‘Win-Win-Win’ for Patients, Public Health, Cost SavingsMarch 20th, 2023
Flu Season Returns Amid COVID-19 Pandemic: Johns Hopkins Medicine Experts AvailableSeptember 27th, 2021
Join now to see all

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/mark-sulkowski